BRII-196 and BRII-198

DRUG3 trials

Sponsors

Brii Biosciences Limited, Brii Biosciences, Inc.

Conditions

COVID-19

Phase 1

A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

CompletedNCT04691180

Brii Biosciences LimitedCOVID-19

Start: 2021-01-05End: 2021-09-16Updated: 2023-03-03

Phase 2

A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19

WithdrawnNCT04770467

Brii Biosciences, Inc.COVID-19

Start: 2021-02-28End: 2022-10-31Updated: 2023-03-03

A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

CompletedNCT04787211

Brii Biosciences LimitedCOVID-19

Start: 2021-06-20End: 2021-12-02Updated: 2023-03-03

Related Papers

Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults

Frontiers in Pharmacology2022-09-0611 citations